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Abstract
Background: Under the direction and sponsorship of the National Cancer Institute, we report on the first pre-clinical trial of
the Comparative Oncology Trials Consortium (COTC). The COTC is a novel infrastructure to integrate cancers that naturally
develop in pet dogs into the development path of new human drugs. Trials are designed to address questions challenging
in conventional preclinical models and early phase human trials. Large animal spontaneous cancer models can be a valuable
addition to successful studies of cancer biology and novel therapeutic drug, imaging and device development.
Methodology/Principal Findings: Through this established infrastructure, the first trial of the COTC (COTC001) evaluated a
targeted AAV-phage vector delivering tumor necrosis factor (RGD-A-TNF)t oaV integrins on tumor endothelium. Trial
progress and data was reviewed contemporaneously using a web-enabled electronic reporting system developed for the
consortium. Dose-escalation in cohorts of 3 dogs (n=24) determined an optimal safe dose (5610
12 transducing units
intravenous) of RGD-A-TNF. This demonstrated selective targeting of tumor-associated vasculature and sparing of normal
tissues assessed via serial biopsy of both tumor and normal tissue. Repetitive dosing in a cohort of 14 dogs, at the defined
optimal dose, was well tolerated and led to objective tumor regression in two dogs (14%), stable disease in six (43%), and
disease progression in six (43%) via Response Evaluation Criteria in Solid Tumors (RECIST).
Conclusions/Significance: The first study of the COTC has demonstrated the utility and efficiency of the established
infrastructure to inform the development of new cancer drugs within large animal naturally occurring cancer models. The
preclinical evaluation of RGD-A-TNF within this network provided valuable and necessary data to complete the design of
first-in-man studies.
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Introduction
The current cancer drug development path involves a linear
development plan that includes assessment of efficacy in small
animals and safety assessments in non-tumor bearing large animals
that lead to first-in-man clinical trials. For many reasons this
preclinical development process has been criticized for its inability to
identifydrugs that aremostlikelytosucceed inthe human clinic. For
example the use of one species (i.e. rodents) to define efficacy and a
second species to define safety (i.e. the dog) precludes assessment of
therapeutic index until an agent actually enters early phase human
studies. The biological complexity and heterogeneity of cancer is not
adequately represented by the numbers of rodent tumor models
commonly used in preclinical efficacy screening [1]. Complex
relationships between drug exposure and necessary biological
changes in tumor tissue or circulating space are not easily modeled
in murine cancers. As a result, many questions are left unanswered
before early phase human studies. Similar if not more pressing
questions persist following early phase human trials that may
significantly limit the optimal design of later phase human studies.
Spontaneous cancers in companion (pet) dogs offer a unique,
and largely unexploited translational research opportunity for
PLoS ONE | www.plosone.org 1 March 2009 | Volume 4 | Issue 3 | e4972cancer imaging, device and drug development [2,3]. This field of
study, known as comparative oncology, has a long history of
advancing surgical techniques, such as limb sparing for pediatric
sarcoma patients, elucidating hyperthermia and radiobiology, and
evaluating novel anti-cancer agents and delivery mechanisms,
including inhalation cytokine and chemotherapy strategies
[4,5,6,7,8,9]. The features and use of cancers in pet dogs that
may contribute to our understanding of cancer pathogenesis,
progression and therapy have also been recently reviewed [2]. The
opportunity to assess drug exposures, toxicity and efficacy
(therapeutic index) in a single large animal model is highly
informative. These cancers more accurately recapitulate the
heterogeneity and complexity of human malignancies and as a
result are linked to the problems of recurrence, resistance and
metastasis. The size of the dog and tumors in these dogs make
assessment of correlative endpoints such as pharmacodynamic
changes in a tumor or secondary tissue quite feasible. Accordingly,
these models are well suited to be integrated with existing model
approaches and optimize the drug development path.
In order to take advantage of the model opportunities provided
by pet dogs that have naturally developed cancer, the National
Cancer Institute’s Center for Cancer Research-Comparative
Oncology Program (CCR-COP) has recently developed an
infrastructure that is capable of multi-center nation-wide trials in
tumor-bearing dogs using cancer drugs that are under develop-
ment for human patients. Referred to as the Comparative
Oncology Trials Consortium (COTC), this infrastructure includes
18 state-of-the-art academic veterinary oncology centers. COTC
trials are centrally managed and designed to include multiple
endpoints that define safety, biological and clinical activity of novel
treatment agents.
The first completed trial of the COTC is an example of a
pharmacodynamically focused study conducted to directly inform
next step decisions in the clinical development of an adeno-
associated virus phage [10,11,12] delivery of tumor necrosis factor-
a (RGD-A-TNF)t oaV integrins to tumor and tumor-associated
vascular endothelium. The development of anti-angiogenic and
vascular-targeted agents has been complex and with incommen-
surate results from studies in tumor-bearing mice and human
cancer patients [13,14]. It is reasonable that that some of the
attributes of the comparative oncology approach may be
particularly informative in the evaluation of both anti-angiogenic
agents and novel gene delivery methods [15]. Accordingly, the first
trial of the COTC has evaluated this ligand-direct targeting gene
delivery system [10,11,12,16,17,18]. Through a step-wise trial
design we demonstrated the safety, tumor-selective trafficking, and
anti-tumor activity of RGD-A-TNF to tumor blood vessels and
targeted expression of TNFa in a relevant clinical setting. These
results provide a strong pre-clinical basis for first-in-man studies in
human cancer patients. In a larger context, this report of the first
clinical trial from the COTC, suggests that the existing population
of dogs with spontaneous tumors and this advanced clinical trial
infrastructure can serve as an efficient intermediate step in the
translation of new cancer treatments from pre-clinical models to
man.
Results
Dose-escalation and single-dose safety trial phase
Modified Fibonacci rules of dose escalation were followed
within five dose cohorts (n=3) each receiving a single adminis-
tration of RGD-A-TNF (Fig 1A, Table 1). All dogs underwent pre-
treatment biopsy of tumor and normal tissues (Fig 1B). Dogs in the
initial five cohorts (n=18) received RGD-A-TNF followed by
definitive surgical resection of their tumors four days later (tumor
and control normal tissues were collected post treatment); an
additional sixth cohort (n=6) received RGD-A-TNF and under-
went definitive surgery on the same day (4–6 hours following
intravenous administration) (Fig 1B). At enrollment in the dose-
escalation trial phase of the study, there were 9 primary bone
sarcomas and 15 soft tissue sarcomas (oral cavity 3; axial or
appendicular 12) (Table 1). Age (range, 2.7–14.1 years; median
9.7 years), weight (range, 15–61.2 kg; median 34.4 kg) and breed
(11 mixed-breed and 13 purebred) of the dogs that entered this
trial phase were recorded.
All data were reported by contemporaneous electronic report-
ing such that adverse events were uniformly monitored and
managed within this multi-center COTC trial design. Single-doses
of RGD-A-TNF were for the most part well tolerated in all dose-
escalation cohorts planned for this phase of the study. The only
significant adverse event observed occurred during the intravenous
infusion of RGD-A-TNF in the highest dose cohort (10
13 TU),
where a single dose-limiting toxicity (DLT) was noted (Dog #1.18;
Grade 3 hypersensitivity reaction); this event (nausea, tachycardia,
and hypotension) was transient and resolved with minimal
supportive care. Three additional dogs were entered into this
dose cohort with no further toxicity observed. No maximally
tolerated dose (MTD) was reached since the highest dose failed to
result in any dose limiting toxicities. There were no clinically
significant neurological, cardiac, respiratory, gastrointestinal,
renal, or hematologic toxicities related to the treatment of the
Figure 1. Schema representing the schedule for the dose
escalation phase of RGD-A-TNF evaluation in dogs with
spontaneous cancers. (A) This study was structured as a dose-
escalation using a modified Fibonacci design to govern dose escalation
towards an MTD. (B) Three dogs were enrolled in the starting-dose
cohort, and three dogs per cohort were enrolled there after for each of
the five dose levels planned. Dogs were scheduled to receive RGD-A-
TNF on day zero and to undergo definitive tumor resection 4 days later.
This initial 4-day group was designed (i) to evaluate vector localization
and TNFa expression within tumors and (ii) to verify that the tentative
follow-up schedule of RGD-A-TNF administration at one-week dosing
intervals was biologically appropriate. After a group of dogs (n=18)
were treated according to this schedule, an additional group was
enrolled by equivalent inclusion criteria to receive RGD-A-TNF on the
same day of definitive surgical resection. In this subset of dogs (n=6),
surgery was performed 4–6 hours post administration of RGD-A-TNF,
this same-day experimental subset was designed to establish the acute
selectivity of RGD-A-TNF trafficking and its tumor vascular localization.
doi:10.1371/journal.pone.0004972.g001
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delays in wound healing (surgical incision) detected, or febrile
episodes associated with single-doses of RGD-A-TNF These data
suggest that RGD-A-TNF was safe following intravenous admin-
istration of a single dose of RGD-A-TNF up to 10
13 TU. Since no
MTD was achieved, it is possible that higher single doses of RGD-
A-TNF may also be safely administered.
Trafficking to tumor vascular endothelium and targeted
TNFa delivery
To determine if RGD-A-TNF trafficked to tumor versus normal
tissues, we analyzed pre-treatment and post-treatment (after 4–
6 hours and after 4 days) biopsies of tumor and normal tissues (i.e.,
oral mucosa, skin, and muscle) following a single dose of RGD-A-
TNF by dual-color immunofluorescence (IF) staining for phage
(Fig. 2A, B). The staining pattern of all biopsy samples were scored
as positive or negative as described (Methods). Clear co-
localization of RGD-A-TNF particles were seen only within tumor
vascular endothelium in tumor biopsies, but not in the blood
vessels of normal tissues, as early as 4 to 6 hours post-treatment
(Fig. 2A) and at 4 days post-treatment (Fig. 2B). The specificity of
the IF assay was supported by the lack of staining seen in the pre-
treatment biopsies in any dogs (Fig. 2A, B). Secondarily, there was
no tumor cell RGD-A-TNF staining evident, only tumor vascular
endothelium staining. We observed heterogeneous RGD-A-TNF
staining patterns in different sections from the same tumor biopsy
and in different biopsies within the same tumors. This reflects the
heterogeneity of tumor vasculature biology in spontaneous cancer
that led to differential uptake of RGD-A-TNF in tumor tissues.
Consistent trafficking of RGD-A-TNF to tumor blood vessels was
observed in the two cohorts receiving the highest doses;
specifically, two out of three dogs (67%) in the cohort that
received 5610
12 TU and five out of six dogs (83%) in the cohort
that received 1610
13 TU. There was no apparent association
between tumor histology and tumor vascular targeting.
After establishing that RGD-A-TNF preferentially localizes
within tumor vascular endothelium after systemic administration,
we next evaluated whether vector localization would result in
targeted TNFa gene expression. Three out of the four dogs tested
for hTNFa gene expression showed significantly increased levels of
hTNFa in post-treatment tumor biopsies (day 4) compared to pre-
treatment tumor biopsies (Kruskal-Wallis test p=0.0107) after a
single dose of RGD-A-TNF (Fig. 2C). In contrast, post-treatment
biopsies of normal tissues showed no detectable increase in levels
of hTNFa compared to pre-treatment tumor biopsies (Kruskal-
Wallis test, p.0.05).
Multi-dose phase of study
In the multi-dose phase of the study, a cohort of dogs (n=18)
was enrolled and serially treated with fixed systemic doses (5610
12
Table 1. RGD-A-TNF Dose Escalation Study: Patient Population and RGD-A-TNF Trafficking Data
Dose (TU) Cohort *Patient I.D. Post tx. biopsy Tumor histology Tumor location Age (yrs) Weight (kg) IF
4610
11 1 1.1 day 4 OCS Oral-maxilla 9.1 25.0 +
4610
11 1 1.2 day 4 **PCT Oral-maxilla 12.0 29.6 2
4610
11 1 1.3 day 4 **BCT L Forelimb 14.1 32.7 +
4610
11 1 1.4 day 4 OS R Proximal Humerus 7.0 30.3 2
4610
11 1 1.5 day 4 NST (STS) R Forelimb 8.1 37.2 2
4610
11 1 1.6 day 4 STS R Hindlimb 11.0 36.4 2
8610
11 2 1.7 day 4 NST (STS) L Forelimb 12.8 32.7 2
8610
11 2 1.8 day 4 STS L Hindlimb 9.9 44.0 2
8610
11 2 1.9 day 4 NST (STS) R Forelimb 8.6 45.9 2
1610
12 3 1.10 day 4 FS Oral-mandibular 9.4 35.0 N.A.
1610
12 3 1.11 day 4 NST (STS) R Thorax 9.6 32.0 2
1610
12 3 1.12 day 4 STS R Hindlimb 7.7 34.2 2
5610
12 4 1.13 day 4 OS L Tibia 10.1 32.6 +
5610
12 4 1.14 day 4 STS R Hip/thigh 12.5 16.3 2
5610
12 4 1.15 day 4 STS Thorax 2.7 44.9 +
1610
13 5 1.16 day 4 OS R Radius 4.5 41.0 2
1610
13 5 1.17 day 4 STS R Thorax 10.7 40.0 +
1610
13 5 1.18 day 4 OS L humerus 10.9 34.5 +
4610
11 1 1.19 4–6 hr OS R Femur 10.9 33.3 2
4610
11 1 1.20 4–6 hr OS R Tibia 11.4 31.8 +
4610
11 1 1.21 4–6 hr OS R Humerus 9.5 43.0 2
1610
13 5 1.22 4–6 hr OS L Radius 6.2 42.3 +
1610
13 5 1.23 4–6 hr OS R Radius 9.8 61.2 +
1610
13 5 1.24 4–6 hr NST L Axilla 8.1 15.0 +
TU: transducing units; IF: immunoflourescent staining for presence of RGD-A-TNF in tumors; OCS: osteochondrosarcoma; PCT: plasma cell tumor; BCT: basal cell tumor;
NST: nerve sheath tumor; STS: soft tissue sarcoma; OS: osteosarcoma; FS: fibrosarcoma; N.A.: not analyzed due to improper shipment.
*Patient I.D.: dog is identified as participating in study 1 (dose escalation study), followed by patient number (i.e. patient 1.2 is dog 2 in study 1 and so on);
**These two tumors originally diagnosed as soft tissue sarcomas were reclassified upon histopathologic review by a single pathologist (SN).
doi:10.1371/journal.pone.0004972.t001
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obtained pre-treatment (deemed day zero) and on days 7, 28 and
56 post-treatment (Fig 3). At enrollment in the multi-dose phase of
the study, pathological tumor types (Table 2) included soft tissue
sarcomas (n=8), malignant melanomas (n=5), osteosarcoma
(n=1), multilobular osteochondrosarcoma (n=1), hemangiosar-
coma (n=1), lymphoma (n=1), and squamous cell carcinoma
(n=1). All tumors were located at peripheral sites that were
accessible to biopsy; however, concurrent metastatic disease
existed in two dogs. Age (range, 6–14.8 years; median 10.2 years),
weight (range, 11–55 kg; median 33.3 kg) and breed (7 mixed-
breed and 11 purebred) of the dogs that entered this trial phase
were recorded (Table 2).
Serial, multiple fixed doses (total, 78.25 doses; mean 4.34 doses/
dog; range, 1–8 doses/dog) were administered. Fourteen dogs in
this cohort (78%) completed at least one full cycle (defined as four
weekly doses) of treatment and were included in the treatment-
received population for assessment of tumor response. Death due
to disease progression (n=2) or study withdrawal by owner request
(n=2) was the most common reason for dogs to fail completion of
treatment cycle 1. Three of 14 dogs (21%) completed a second full
cycle (i.e., eight weekly doses) of treatment.
Similar to the dose-escalation phase of the study, all data was
electronically reported within the format of this COTC multi-
center trial design. Furthermore, the same clinical evaluation,
imaging, and laboratory studies were obtained before and after the
administration of each weekly dose of RGD-A-TNF. In dogs that
received repetitive weekly doses, the most common toxicity (n=9)
was a grade 3 hypersensitivity reaction during intravenous
administration; six dogs out of 14 (42%) had more than one
clinical episode (i.e., vomiting, hypotension, and tachycardia) that
was not prevented by pre-medication (famotidine, diphenhydra-
mine and dexamethasone). However, all of these adverse events
were transient and resolved following temporary pause (,30 min)
of administration and minimal supportive care, after which a
slower intravenous infusion rate (100 ml/hour) was resumed
without further complications. There were no apparent long-term
clinical sequelae to these events. Grade 3 or 4 non-neutropenic
fever was noted in five dogs (36%) in the study (three noted during
the infusion and two on non-administration days). All fever
episodes resolved with symptomatic care. One case (Dog #2.2)
presented with grade 3 necrosis (open wound and drainage at the
tumor site) on treatment day 19; this same dog had an 18%
reduction in tumor size at that time (defined by RECIST as stable
Figure 3. Schema representing the schedule for the multi-dose phase of RGD-A-TNF evaluation in dogs with spontaneous cancers.
This study was designed as an open label, multiple fixed-dose trial (i) to establish feasibility and (ii) to identify chronic and/or cumulative toxicity of
repetitively administered RGD-A-TNF. Dogs received weekly doses (5610
12 TU intravenously) of RGD-A-TNF. Anticancer activity of this agent was
evaluated using RECIST criteria. The treatment received population included dogs that received at least four weekly doses (i.e., one cycle 1). This
population consisted of 14 dogs. Dogs were permitted to receive additional therapy in subsequent cycles if there was evidence of either stable
disease or tumor response. Tumor measurements were recorded every two weeks with full restaging every 28 days.
doi:10.1371/journal.pone.0004972.g003
Figure 2. RGD-A-TNF trafficking resulted in selective tumor endothelial cell localization and TNFa expression. (A, B) RGD-A-TNF
selectively targeted tumor-associated vasculature (arrows) and was absent from normal tissues at 4–6 hours (A) and at 4 days (B). Magnification, 400-
fold; scale bar, 100 mM. Pre-treatment tumor biopsies, post-treatment tumor biopsies, and post-treatment normal tissues in dogs that received a
single-dose of RGD-A-TNF double-stained with an anti-CD31 specific antibody plus an anti-bacteriophage specific antibody. Detection was performed
with Alexa Fluor 488 (green, blood vessels), Alexa Fluor 594 (red, AAVP), and DAPI (blue, cell nuclei). (C) Pre-treatment tumor biopsies (day 0), post-
treatment normal biopsies (day 4) and post-treatment tumor biopsies (day 4) were used for extraction of total RNA. RT-PCR was performed to
measure transcript levels of human TNFa in quadruplicate. The Y-axis represents the relative TNFa expression levels in post-treatment normal
biopsies and post-treatment tumor biopsies compared to pre-treatment tumor biopsies after normalization to GAPDH expression (Kruskal-Wallis Test,
p=0.0107). All data are presented as means6standard deviations. (D–F) Presence of RGD-A-TNF was evaluated in post-treatment (day 28) necropsy
samples of tumor (D) and normal tissues (E, F). Tissues were stained for RGD-A-TNF as described earlier. RGD-A-TNF selectively targeted tumor-
associated vasculature in post-treatment tumor samples (arrows). In contrast, the vector was not apparent in pre-treatment tumor samples or in post-
treatment normal control necropsy samples (such as lung, liver, spleen or intestine) after serial administrations of RGD-A-TNF.
doi:10.1371/journal.pone.0004972.g002
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including a grade 2 skin reaction associated with demodectic
mange (Demodex canis), a grade 1 ventricular arrhythmia, and a
first-event-death of unknown cause two days after the fifth dose of
RGD-A-TNF. In the first-event-death case, no adverse events were
noted (Dog #2.14) during the week prior to this event. First-event-
death in dogs with advanced cancer (not unlike early phase human
trials) is not uncommon and may be associated with disease
progression, particularly when observed as isolated events. No
other significant adverse events including clinical or laboratory
reports of neurological, cardiac, respiratory, gastrointestinal, renal,
or hematologic toxicity related to serial treatment with RGD-A-
TNF were seen. Three dogs out of 14 (21%) were euthanized due
to progressive disease and underwent rapid (warm) necropsy;
pathologic evaluation of visceral organs (brain, heart, lung, liver,
spleen, gastrointestinal tract, kidneys, and lymph nodes) did not
detect any treatment related histologic abnormalities in these
organs; data supporting the relative safety and tumor-targeting of
RGD-A-TNF. In select warm necropsy cases (n=2), two-color IF
was performed and tumor-specific trafficking of RGD-A-TNF was
seen (Fig. 2D); no RGD-A-TNF was detected in examined normal
tissues (lung, liver, spleen, and gastrointestinal tract) (Fig. 2E, F).
Treatment-associated objective response
In the treatment-received population of 14 dogs, we used serial
tumor measurements to determine the activity of RGD-A-TNF
according to the Response Evaluation Criteria in Solid Tumors
(RECIST) (Table 2). Again, the four dogs that failed to complete
one cycle (4 weeks) of therapy were excluded for evaluation of
response. Evaluable dogs included those with tumors not
amenable to surgical excision, tumors for which prior therapy
had failed, and tumors in which standard-of-care therapy was
declined. Two animals (Dogs #2.11 and #2.16) had a RECIST-
defined partial response (PR) (14%; 95% confidence interval 2–
43%) one at day 28 and the other at day 56 (Table 2). Six dogs had
stable disease (SD) (43%; 95% confidence interval 18–71%)
including a dog with an 18% reduction in tumor size, and six dogs
had disease progression (PD) (43%; 95% confidence interval 18–
71%) after one cycle of therapy. After two cycles of therapy, two of
the dogs with previously defined stable disease at Day 28
progressed (Table 2). The case of a marked clinical PR is depicted
to illustrate the magnitude of the serial therapeutic effect of RGD-
A-TNF in a dog presenting with a large soft tissue sarcoma (Fig. 4).
This dog (#2.11) had achieved an $85% reduction in what had
previously been unresectable disease. Following this response a
,2 cm residual lesion was resected resulting in a pathological
review revealing no viable tumor. These results support the
previous studies evaluating the safety and activity of this strategy in
tumor-bearing rodent models [10,19].
RGD-A-TNF directed immune response in treated dogs
We analyzed pre-treatment and post-treatment serum samples
from single-dose and serial multi-dose study dogs to measure anti-
AAVP antibodies. Collectively, we observed 1.8 to 2.0 fold
increases in anti-AAVP antibody titers post treatment when
compared to pre-treatment levels. However, we did not observe
further increases in anti-AAVP antibodies over time in the serial
multi-dose treated dogs (Day 7 vs. Day 28 vs. Day 56).
Table 2. RGD-A-TNF Multiple Dose Study: Patient Data and Tumor Responses
*Patient
I.D. Tumor histology Age (yrs)
Cycle 1 tumor
measurements day0/
day14/day28 (cm)
Cycle 1 Response
(% change)
Cycle 2 tumor
measurements day28/
day42/day56 (cm)
Cycle 2 Response
(% change)
2.1 FS 11 5.0/7.0/9.5 PD (90% inc.)
2.2 Sarcoma 10.2 23.0/21.0/19.0 SD (18% dec.)
2.3 Melanoma 12.8 2.0/2.0/2.0 SD (0%)
2.4 Sarcoma 14.8 14.7 Unevaluable
2.5 Sarcoma 10.4 6.8/8.5/8.2 PD (21% inc.)
2.6 OS 9 3.2/4.5/7.4 PD (130% inc.)
2.7 Lymphoma 8.6 11.6/14.2 SD 14.2/15.8 PD (11% inc, uveitis)
2.8 Hemangiosarcoma 7.1 6.5/8.2/6.5 SD (0%) 6.5/7.1/6.5 PD (pulm mets)
2.9 PNST 10.3 5.6 Unevaluable
2.10 SCC 12.8 4.6 Unevaluable
2.11 S-C MS 9.9 12.3/7.0/8.2 PR (33% dec.) 8.0/2.9/1.85 PR (85% dec.)
2.12 PNST 8.8 4.0/4.2/4.5 SD (12% inc.)
2.13 PNST 12.1 6.6/8.0/8.1 PD (22% inc.)
2.14 Melanoma 11 3.9/4.6/6.0 PD (54% inc.)
2.15 MLT 6.3 3.5/3.5/3.5 SD (0%)
2.16 Mel – LN mets 10 3.5/3.0/2.6 SD (26% dec.) 2.6/2.2/2.3 PR (33% dec.)
2.17 Melanoma 11 9.0/5.5/5.8 Unevaluable
2.18 Melanoma 6 14.6/23.2 PD (59% inc.)
FS: fibrosarcoma; OS: osteosarcoma; PNST: peripheral nerve sheath tumor (malignant); SCC: squamous cell carcinoma; S-C MS: subcutaneous myxosarcoma; MLT: multi-
lobular tumor; Mel: LN mets: melanoma lymph node metastases; inc.: increase; dec.: decrease; PD: progressive disease; SD: stable disease (shown in yellow); PR: partial
response (shown in green); Unevaluable: due to consent withdrawal by the owner, or death or euthanasia before completion of cycle 1
*Patient I.D.: dog is identified as participating in study 2 (fixed multiple dose study), followed by patient number (i.e. patient 2.2 is dog 2 in study 2 and so on)
Cycle 1: dogs received 4 weekly doses of RGD-A-TNF; Cycle 2: dogs received additional 4 weekly doses of RGD-A-TNF
doi:10.1371/journal.pone.0004972.t002
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The opportunity to integrate cancers that naturally develop in
pet dogs within the development path of a novel human cancer
drug is further realized through the inaugural study of the COTC.
In this report, we describe a targeted delivery of TNFa with an
AAVP gene delivery system to tumor blood vessels of pet dogs with
spontaneous cancer. Selective AAVP homing, tumor-associated
vascular expression of TNFa, systemic safety, and RECIST-based
objective responses were observed (same species therapeutic
index). These large animal spontaneous cancer models are well
suited to inform pre-clinical to clinical transitions necessary for
successful drug development and compliment the use of both
existing rodent models and human clinical trials.
The COTC is an active network of academic comparative
oncology centers, centrally managed by the NCI’s Comparative
Oncology Program. The COTC designs and implements clinical
trials in dogs with cancer with the goal of providing necessary
translational data for novel therapies, techniques or devices for
future cancer patients. Trials are executed at COTC member
institutions, which currently include eighteen veterinary teaching
hospitals across the United States. As described above, trials
conducted by the COTC may include several biological and
clinical endpoints that can be directly integrated into the design of
human Phase I and II clinical trials. Although not included in the
study presented here, correlative imaging strategies, such as PET/
CT or dynamic MRI, with the ability to link these imaging
endpoints to tumor or circulating biological surrogates are feasible
through the designed infrastructure. Such complex correlative
studies may be vetted in a clinically relevant setting through
COTC studies, and therein provide a model to evaluate all parts of
this process including tissue collection standards and techniques,
timing of imaging and biopsy, and assay methodologies prior to
early phase human studies.
In the current study, COTC001, we assessed the fluidity and
structure of this novel preclinical infrastructure. In the process, we
defined the safety and efficacy of RGD-A-TNF targeting to tumor
endothelium in pet dogs with spontaneous cancer. RGD targeted
delivery to tumor aV integrins has been previously described
[20,21] and this anticipated targeting was the basis of the RGD-A-
TNF vector development [11,19,22]. In previously published work
in mouse xenograft models, we described targeted systemic delivery
ofRGD-AVVPvectorsexpressingeitherHSVtkorTNF-a,totumor
vasculature [12,22,23,24]. Anti-tumor activity has been seen in
Kaposi sarcoma, bladder carcinoma, prostate carcinoma and
melanoma [12,22]. Although, activity of RGD-A-TNF has been
demonstrated in traditional small animal models, the comparative
oncology approach provided unique information regarding the
safety of RGD-A-TNF that would not have been possible in
conventional animal safety studies. Since neither tumor nor tumor
vasculature are present in healthy animals (i.e. purpose-bred
research dogs), a safety assessment in these animals would likely
under-report adverse events related to RGD-A-TNF. Drug-related
events reported in our population of tumor-bearing pet dogs were
indeed generally mild and self-limiting. In fact, a MTD was not
achieved in the single dose cohorts evaluated in the dose-escalation
as increasing the dose of RGD-A-TNF was limited by manufacture
process. Most adverse events that were documented were seen
either during the administration or within 2 hours of administration
in dogs that had received multiple doses of RGD-A-TNF.
Figure 4. RGD-A-TNF administration resulted in objective tumor responses in dogs with spontaneous cancers. A large primary soft
tissue sarcoma on the flank of Dog #2.11 is shown to feature the potential magnitude of the tumor response. Prior to therapy (day 0), the tumor
measured 12.3 cm in longest diameter. At day 28, after 4 weekly infusions of RGD-A-TNF, the tumor measured 8.2 cm in longest diameter (a 33%
regression) and a RECIST-based partial response (PR). At day 56, after a total of 8 weekly systemic infusions of RGD-A-TNF, the tumor measured
1.85 cm in longest diameter prior to resection. Therefore, this response equated to an 85% regression from baseline and a continued clinical PR.
Upon surgical resection of the residual lesion, no viable tumor was found and a pathological complete response was determined.
doi:10.1371/journal.pone.0004972.g004
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tions and fever. Given the per-acute nature of these events, it is
plausible that such they were related either to undetectable remnant
endotoxin in the treatment product or to a specific response to the
vector itself. Testing of all production lots of RGD-A-TNF failed to
reveal residual endotoxin; however, one cannot entirely exclude this
or other contaminants as a cause of some of the adverse events.
Serial tumor and controltissue biopsies taken beforeand after the
administration of RGD-A-TNF provided an opportunity to
correlate drug exposure with tumor and normal tissue trafficking
of RGD-A-TNF. These experiments validated the tumor-specific
targeting of the RGD-A-TNF in the setting of dogs with
spontaneous cancers. We observed vector localization in tumor
vascular endothelium in post-treatment tumor biopsies taken 4–
6 hours and 4 days after systemic administration of RGD-A-TNF.
Notably, therewasa completeabsence ofthe vectorinnormal tissue
biopsies in all treated dogs. Thus, RGD-A-TNF exploits aberrant
disease-related vasculature to target the therapy of interest
specifically to the tumor. Thus confirming the safety of this delivery
system first observed in our small animal models [22]. Consistent
with this, warm necropsies from dogs euthanized due to disease
progression showed that RGD-A-TNF targeted tumor vasculature
but not blood vesselswithin normal visceralorgans. Importantly,we
did not observe RGD-A-TNF in any of the control tissues analyzed,
including liver whereas the presence of RGD-A-TNF has been
previously seen in the liver and spleen of rodents treated with RGD-
A-TNF [22]. These large animal data are particularly valuable as
the risks and benefits for AAVP delivery strategies in human cancer
patients are considered. Effective targeting of RGD-A-TNF was
seen at doses from 5610
12 to 10
13 TU. A dose of 5610
12 TU was
selected as optimal dose for the multiple-dose study, due to
equivalent trafficking, targeting, and safety as well as our inability to
produce 1610
13 TU in a timely manner. At this dose vector
targeting also resulted in measurable expression of human TNFa.
Further support for the biological relevance of the observed
trafficking of RGD-A-TNF along with targeted expression of
human TNFa, was provided by the objective anti-tumor activity
observed in dogs receiving multiple weekly treatments. RECIST-
based responses were observed in two dogs with soft tissue sarcoma
and metastatic melanoma; such objective tumor responses are
particularly germane, because all dogs in this study had large bulky
tumors and were not candidates for conventional loco-regional
treatments such as surgery or radiation therapy. We speculate that
the observed objective responses were the result of TNFa transgene
expression, as no activity was seen in our mouse models from either
non-targeted AAVP or targeted-null vector [22]. The proposed
mechanism for this activity is the induction of endothelial cell
apoptosis and hyperpermeability leading to hemorrhagic necrosis in
treated tumors [25,26,27]. This biology will be further explored in
planned canine studies using Good Manufacturing Practice (GMP)
quality RGD-A-TNF, via caspase-3 and CD31 staining. However, it
is important to note that the future development strategy for this
delivery system is not as a single agent. Instead it will likely involve
combinational therapies, either dual transgene insertion or adjunct
administration of complementary agents. Hence its single agent
activity is note worthy.
In summary, the biological complexity of naturally occurring
cancers in pet dogs, their size and strong similarities to human
cancers, and the availability of a motivated population of pet-
owners interested in treatments for their pets with cancer provide
an opportunity to now develop a comparative and integrated
approach to cancer drug development. [1,2,3]. The first study of
the COTC (COTC001) provides an example of this integration
and a functional infrastructure that may deliver trial outcomes in a
timely manner. Specifically, COTC001 assessed the safety,
selective tumor-specific localization, and anti-tumor activity of
RGD-A-TNF in dogs with measurable malignant cancers. This
report supports a new paradigm for rapid intermediate evaluation
of agents prior to or after early human trials as a means to creating
a more informed and optimal cancer drug development pathway.
Materials and Methods
Comparative Oncology Trials Consortium
The over-riding goals and infrastructure of the COTC have
been recently described [2,3]. This report represents the first
clinical trial in dogs with cancer through this multi-institutional
consortium. All COTC trial data was reported electronically and
contemporaneously reviewed through a modified form of Oracle
Clinical, known as the Cancer Central Clinical Database (C3D),
developed through the NCI’s CCR and Cancer Bioinformatics
Grid (CaBIG), modified for use in canine clinical trials [28].
Trial eligibility and enrollment
Client-owned pet dogs with biopsy-proven malignant tumors
(newly-diagnosed or recurrent disease) with favorable performance
status (Grade 0 or 1 Modified ECOG Performance Status), and
informed owner consent were eligible for enrollment. For the dose-
escalation phase, entry criterion was an externally measurable tumor
(.2 cm in the longest diameter) that was amenable to surgical
resection. For the multiple-dose trial phase entry criteria included
measurable tumors of greater than 3 cm in the longest diameter.
Physical examination, laboratory studies, and imaging studies were
performed to evaluate eligibility prior to enrollment (Figs 1 & 3).
Specifically, complete blood count, biochemical screening profile,
urine analysis, prothrombin time and partial thromboplastin time,
and a baseline electrocardiogram were required. Exclusion criteria
removed dogs weighing less than 15 kg, those with significant co-
morbidities (such as renal, liver, and heart failure or coagulopathy) a
diagnosis of mast cell cancer, or concurrent chemotherapy, radiation
therapy, or biological therapy. Tumor staging included thoracic
radiographs and abdominal ultrasound when clinically indicated.
Dogs with metastatic disease were excluded from entry in the dose-
escalation phase (Table 1) but were allowed in the multiple-dosing
phase of the trial (Table 2). All dogs were evaluated uniformly and
treated in a defined clinical protocol with Institutional Animal Care
and Use Committee (IACUC) approval at each COTC enrollment
site (Colorado State University, University of Missouri, University of
Pennsylvania, University of Tennessee, and University of Wisconsin).
The NCI-COP reviewed the eligibility screening and approved trial
entry of each individual dog.
Dose-escalation phase
This study was structured as a dose-escalation using a modified
Fibonacci design to govern dose escalation towards a MTD (Fig 1).
Threedogs were enrolledinthestarting-dosecohort,andthree dogs
per cohort were enrolled thereafter for each of the five dose levels
planned (Fig 1A, Table 1). Dogs were scheduled to receive RGD-A-
TNF on day zero and to undergo definitive tumor resection 4 days
later (Fig 1B). This initial 4-day group was designed (i) to evaluate
vector localization and TNFa expression within tumors and (ii) to
verify that the tentative follow-up schedule of RGD-A-TNF
administration at one-week dosing intervals was biologically
appropriate. After a group of dogs (n=18) were treated according
to this schedule, an additional group was enrolled by equivalent
inclusion criteria to receive RGD-A-TNF on the same day of
definitive surgical resection (Fig 1B). In this subset of dogs (n=6),
surgery was performed 4–6 hours post administration of RGD-A-
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the acute selectivity of RGD-A-TNF trafficking and its tumor
vascular localization. After surgery, dogs returned to their
participating institution for suture removal and surgical wound re-
evaluation at day 14 postoperatively. A standard physical
examination was performed at that time.
Multi-dose trial
Thisstudy was designed as anopenlabel,multiple fixed-dose trial
(i) to establish feasibility and (ii) to identify chronic and/or
cumulative toxicity of repetitively administered RGD-A-TNF
(Fig 3). Dogs received weekly doses (5610
12 TU intravenously) of
RGD-A-TNF. Anticancer activity of this agent was evaluated using
RECIST criteria. The treatment received population included dogs
that received at least four weekly doses (i.e., one cycle 1). This
population consisted of 14 dogs. Dogs were permitted to receive
additional therapy in subsequent cycles if there was evidence of
either stable disease or tumor response. A standard physical exam
was performed at each visit and tumor measurements were
recorded every two weeks with full restaging every 28 days (Fig 3).
Construction and production of RGD-A-TNF
The general design and construction of the AAVP particle has
been described [10,11,12,29]. An AAVP construct expressing
human TNFa was created by ligation of a 880-bp NotI/HindIII
fragment from pG1SiTNFa [30] into the vector pAAV-eGFP/
NotI/HindIII, with replacement of the GFP gene sequence.
Subsequently, AAV-TNFa containing inverted terminal repeats
(ITRs) was ligated into the RGD-4C AAVP/PvuII to obtain the
RGD-A-TNF vectors. RGD-A-TNF is a targeted vector with
binding affinity to aV integrins.
To obtain targeted AAVP particles, RGD-A-TNF was electro-
porated into MC1061 E. coli, and virus particles purified from
culture supernate as described [10,11,12]. Contaminating bacterial
cells were removed by repeated centrifugation at 10,000 rpm for
10 min. The RGD-A-TNF prepared from MC1061 E. coli was used
to purifylarge-scaleAAVP particlesfrom a permissive host bacterial
strain (k91Kan E. coli). After preparation of RGD-A-TNF,
endotoxin was removed using MiraCLEAN endotoxin removal
kits (Mirus Bio Corp., Madison, Wisconsin) with pyrogen-free
materials and under good laboratory practice (GLP) conditions in a
sterile hood equipped with a high efficiency particulate air (HEPA)
filter. Briefly, 0.1 volumes of MiraCLEAN buffer were added to
RGD-A-TNF preparation, followed by vortexing and incubation on
ice for 15 min. After incubation, 0.03 volumes of the EndoGO
extraction reagent were added and the solution was incubated on
ice for 15 min with intermittent vortexing. Samples were incubated
at 50uC for 15 min. Phases were then separated by centrifugation at
13,000 rpm for 2 min, and the upper colorless aqueous phase was
transferred to a new tube. Every batch of RGD-A-TNF was
underwent endotoxin removal (3 cycles). Next, AAVP was tested to
determine endotoxin levels with Limulus Amebocyte Lysate (LAL)
QCL-1000 kits (Cambrex, Walkersville, Maryland). All the
materials used in the assay were validated endotoxin-free.
Consistency among reagent batches was confirmed by standard
infection of human M21 melanoma cells and measurement of
TNFa in the supernatant [22]. For final quality control, RGD-A-
TNF preparations were required to have endotoxin levels of less
than 1.0 EU/ml prior to administration.
Following endotoxin removal, the final preparation was filtered
through a sterile filter. To determine the number of bacterial
transducing units (TU), the permissive host k91Kan E. coli was
infected with serial dilutions of AAVP particles and plated on
Luria-Bertani agar plates containing tetracycline and kanamycin.
TU were determined by counts of the number of bacterial colonies
and were expressed either as TU/ml or as Relative TU.
Product packaging, shipping, and quality control
Each batch of RGD-A-TNF underwent determination of TNFa
titer and protein expression. To assess TNFa expression, we
infected human M21 melanoma cells with 10
5 TU/cell for 3 hours
at 37uC in serum-free RPMI medium. After infection, 10% serum
was added to each well, and incubation was continued. The
medium was replaced 72 hours later. On day 5, the culture
supernate was collected for measurement of secreted human
TNFa levels by ELISA (Invitrogen, Carlsbad, California).
Packaging was done into pyrogen-free sterile vials (Allergy Labs,
Oklahoma City, Oklahoma) in a sterile hood equipped with a
HEPA filter. RGD-A-TNF was diluted in sterile normal saline
(Quality Biologicals Inc., Gaithersburg, Maryland) to a final
volume of 5 ml. Each vial containing the vector RGD-A-TNF was
labeled individually with batch and vial numbers, preparation and
expiration dates, and viral concentration. Whenever a dog was
enrolled in the study with confirmed eligibility, vials were shipped
on ice overnight to the COTC-participating institution, where
they were stored at 4uC until administration. Storage times at
COTC institutions were less than 48 hours.
RGD-A-TNF administration, monitoring, and safety
assessment
Dogs underwent a complete physical examination, baseline
imaging,bloodtestsand appropriatebiopsiespriortotheirreceiving
RGD-A-TNF intravenously. Vital signs (core temperature, pulse,
respiratory rate, arterial bloodpressure),and EKGwere recorded at
baseline. Dogs received the pre-determined dose of RGD-A-TNF
suspended in 100 ml of normal saline as continuous rate infusion
(CRI) over 30 min. Vital signs and EKG recordings were collected
every 15 min during intravenous infusion and hourly for four hours
following administration of RGD-A-TNF. After this immediate
post-treatment period,24-hourmonitoring was required for all dogs
with vital signs/EKG recorded every 4 hours.
Definition of acute and chronic toxicities of single and multiple
doses of RGD-A-TNF was a major goal of the study. Blood
samples were collected to define hematologic and biochemical
DLT. CBC, screening biochemical profile, urinalysis, prothrombin
time, and partial thromboplastin time were evaluated at trial
enrollment, pre-operatively in the dose escalation and prior to
each weekly treatment in the multi-dose study. The Veterinary
Cooperative Oncology Group Common Toxicity Criteria for
Adverse Events (VCOG-CTCAE) was used to determine DLT
[31], defined as any grade 3 or grade 4 (hematologic or non-
hematologic) toxicity. MTD was defined as one dose level below
the maximum achieved in dose-escalation or by chronic toxicities
in the multi-dose trial phase of the study. Any and all adverse
events were collected within an electronic database reporting
system (C3D) [32] that followed strict reporting timelines.
Tissue collection
In the dose-escalation phase of the study, serial biopsies were
required from all dogs to determine the localization of RGD-A-
TNF in tumors and normal tissues. Incisional pre-treatment
biopsies yielded tissue samples that were immediately frozen in
liquid nitrogen and subsequently fixed in 10% formalin. Excisional
post-treatment tumors were acquired surgically through standard
operative techniques. At surgery, at least three sections of each
tumor were sampled at different angles/planes; these samples were
placed separately in 10% formalin, liquid nitrogen and RNAlater
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site distant to the tumor were also sampled in a similar fashion. If
possible, intra-operative ‘‘in-field’’ normal tissues were also
collected. Finally, in the multi-dose phase of the study, pre-
treatment tumor biopsies were collected (as described above for
dose-escalation) and serial post-treatment tissue samples acquired
on days 7, 28 and 56 of treatment if applicable.
Immunofluorescence
To detect the presence of RGD-A-TNF, we stained 5 mM frozen
tissue sections for two-color IF. Briefly, sections were fixed in PBS
containing 1% paraformaldehyde for 10 min, followed by 2 washes
in PBS for 10 min. The tissue was rendered permeable in ethanol:
acetic acid (2:1, vol:vol) at 220uC for 5 min, incubated with Image-
iT FX signal enhancer for 30 min at room temperature (RT), and
washed in PBS. Non-specific binding was blocked with PBS
containing 5% goat serum for 30 min at RT. The primary
antibodies were applied overnight at 4uC as follows: a 1:1,000
dilution of anti-fd bacteriophage antibody (Sigma, St. Louis,
Missouri) and a 1:20 dilution of anti-human CD31 (Dako
Cytomation, Denmark). Sections were washed thrice in PBS for
5 min and were incubated with the secondary antibodies (Invitro-
gen, Carlsbad, California) as follows: a 1:400 dilution of goat anti-
rabbit Alexa Fluor 594 and goat anti-mouse Alexa Fluor 488, for
30 min in the dark. Finally, sections were washed four times in PBS
for 2 min each, mounted in Vectashield mounting medium with
DAPI (Vector Labs, Burlingame, California), and images were
viewed and captured on a confocal fluorescent microscope (Zeiss
LSM 510, Zeiss Inc., Germany). For each sample a minimum of 5
sections were stained and analyzed. For samples where no staining
was observed, an additional 10 sections were stained and analyzed.
RGD-A-TNF trafficking
‘‘Positive’’ RGD-A-TNF IF co-localization was determined if a
tumor or normal tissue sample had evident RGD-A-TNF and
endothelial cell staining in serial biopsies from a given time point.
‘‘Negative’’ staining was determined if no co-localization was evident
in at least 15 sections of serial biopsies from a given time point. Prior
to the study’s initiation, the optimal ‘‘trafficking’’ dose of RGD-A-
TNFwas defined in the study protocol as that which resulted in vector
localization in tumor vasculature but not inthe vasculatureof normal
tissues in at least two out of three dogs of within a dose cohort.
Tumor response assessment
Standardized serial measurements of tumors were made prior to
trial entry and weekly thereafter. The greatest diameter of each
tumor was measured with calipers and was recorded (in cm) in the
database. Target lesions were selected at baseline (pre-treatment)
by physical examination or imaging and used for response
assessment; non-target lesions were similarly identified, however,
serial measurements of these lesions were not required. To
determine objective responses to treatment with RGD-A-TNF we
used RECIST criteria [12,33,34,35,36,37]. CR was defined as
disappearance of all lesions without any new lesion development;
PR, a decrease by 30% or more of the longest diameter or sum of
the greatest diameters of all measured target lesions; SD, any
change in tumor size that did not satisfied PR or PD criteria; PD,
an increase .20% in the greatest diameter or sum of the greatest
diameters of all measured target lesions or any new lesions.
TNFa expression
TNFa mRNA was assessed by RT-PCR with primer-probe
sequences unique to human TNFa inserted into RGD-A-TNF.
Total RNA was isolated from frozen tissues with Trizol (Invitrogen
Corp.) and RNeasy total RNA kit (Qiagen), either in the presence
or absence of DNaseI. First-strand cDNAs were generated from
the total RNA either in the presence or absence of reverse
transcriptase (Invitrogen Corp.). Quantitative RT-PCR was
performed with a Gene Amp 7500 Sequence Detector (Applied
Biosystems). Amounts of PCR products were measured as
fluorescent signal intensity after standardization with a GAPDH
internal control. The following sense (S) and antisense (AS) primers
and probes were designed by the use of Primer Express 2.0
software (Applied Biosystems) for real time RT-PCR analysis:
S5 9 TTCAGCTCTGCATCGTTTTG 39
AS 59CTCAGCTTGAGGGTTTGCTACA 39
Probe 59 FAM-TTCTCTTGGCGTCAGATCATCTTCTC-
GAAC-TAMARA 39
Detection of AAVP antibodies
Presence of canine anti-bacteriophage antibodies was detected
using ELISA techniques. Briefly, 1610
10 RGD-A-TNF particles in
50 ml PBS were coated in 96 well plates and allowed to adhere
overnight at 4uC. Non-adherent particles were removed by
washing with PBS followed by blocking with 5% BSA in PBS
for 1 hr. Serially diluted bacteriophage anti-fd antibody (positive
control) (Sigma, St. Louis, Missouri) or 100 ml of serum samples
were added for 2 hr. Wells were washed seven times with wash
buffer (1% BSA in PBS). The binding was detected using 1:3000
dilution of Protein G separose (Pierce, Rockford, Illinois) for 1 hr,
followed by 30 min incubation with TMB substrate (Pierce,
Rockford, Illinois). Reaction was stopped by addition of 50 ml stop
solution. The color reaction was read at 450 nm using BioRAD
ELISA plate reader. A standard curve was generated by plotting
optical density readings obtained for different serial dilutions of
anti-fd antibody and the antibody titer for unknown samples were
quantified.
Necropsy and expert pathology review
Necropsies were required for all dogs on study. Dogs that were
euthanized due to progressive disease received a full warm post-
mortem examination when possible. Tissues were collected within
20 min and all tumor samples (primary and metastatic) were
frozen in liquid nitrogen and subsequently fixed in 10% formalin.
Control (normal-appearing) visceral organs (liver, spleen, heart,
kidneys, lung, gastrointestinal tract, brain, and lymph nodes) were
also collected, frozen, and fixed. One dog that died at home
received a cold necropsy. A single veterinary pathologist (SN)
reviewed all tissue samples for integrity and histopathologic
evaluation.
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